Jpmorgan Chase & CO Xeris Biopharma Holdings, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding XERS
# of Institutions
141Shares Held
59.9MCall Options Held
148KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$31.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$23.8 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$15.6 Million62.59% of portfolio
-
Center Book Partners LP Greenwich, CT3.48MShares$10.7 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA3.33MShares$10.2 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $416M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...